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Background: We report patient characteristics, treatment pattern and one-year clinical outcome of
nonvalvular atrial fibrillation (NVAF) from Kerala, India. This cohort forms part of Kerala Atrial Fibrillation
(KERALA-AF) registry which is an ongoing large prospective study.
Methods: KERALA-AF registry collected data of adults with previously or newly diagnosed atrial fibril-
lation (AF) during April 2016 to April 2017. A total of 3421 patients were recruited from 53 hospitals
across Kerala state. We analysed one-year follow-up outcome of 2507 patients with NVAF.
Results: Mean age at recruitment was 67.2 years (range 18e98) and 54.8% were males. Main co-
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Strokeco-existing diseases were chronic kidney disease (42.1%), coronary artery disease (41.6%), and chronic
heart failure (26.4%). Mean CHA2DS2-VASc score was 3.18 (SD ± 1.7) and HAS-BLED score, 1.84 (SD ± 1.3).
At baseline, use of oral anticoagulants (OAC) was 38.6% and antiplatelets 32.7%. On one-month follow-up
use of OAC increased to 65.8% and antiplatelets to 48.3%. One-year all-cause mortality was 16.48 and
hospitalization 20.65 per 100 person years. The main causes of death were cardiovascular (75.0%), stroke
(13.1%) and others (11.9%). The major causes of hospitalizations were acute coronary syndrome (35.0%),
followed by arrhythmia (29.5%) and heart failure (8.4%).
Conclusions: Despite high risk profile of patients in this registry, use of OAC was suboptimal, whereas
antiplatelets were used in nearly half of patients. A relatively high rate of annual mortality and hospi-
talization was observed in patients with NVAF in Kerala AF Registry.
© 2020 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Atrial fibrillation (AF) is the common cardiac arrhythmia seen in
clinical practice, associated with high morbidity and mortality.1 AF
is becoming a major public health problem worldwide,2 leading to
increased health care resource utilization with its impact on global
health budget.3,4 Epidemiological data on AF is available mainly
from North America, Europe and Far East.5e9 Significant difference
exists between developed and developing countries on aetiology,
co-morbid conditions, treatment preferences, mortality and
morbidity due to AF.10,11 Even though effective therapies have
evolved in the last 4 decades and newer drugs were introduced for
stroke prevention in AF patients in the last 7e8 years, there is wide
variability in adherence to guideline recommended treatment in
different regions of the world.
Limited information is available on clinical epidemiology,
management and outcome of AF patients from south Asia, partic-
ularly from India.10 In this manuscript, we provide patient charac-
teristics, risk factors, treatment pattern and one-year clinical
outcome of NVAF patients who were prospectively recruited from
53 hospitals located in both rural and urban areas of Kerala state.2. Methods
KERALA-AF registry is an ongoing large prospective cohort
registry of AF patients from Kerala. A total of 3421 AF patients were
enrolled during the year 2016e17. Patients with transient AF due to
causes like acute myocardial infarction, infection, alcohol intoxi-
cation, metabolic abnormalities, post-operative cases and critically
ill patients with life expectancy less than 30 days were excluded.
Each patient was enrolled in the registry after examination by the
cardiologist(s) of participating centres from either in-patient or
out-patient services. Majority of patients were from out-patient
service. Detailed methodology and the baseline findings of the
study is published elsewhere.12 Medical history, physical exami-
nation, New York Heart Association (NYHA) status and laboratory
investigations including echocardiography were done at baseline.
Patients were classified into AF with valvular heart disease
(AFVHD) and nonvalvular AF (NVAF).13,14 AFVHD is defined as those
cases associated with mitral stenosis, prosthetic valve implantation
andmitral valve repair. Findings from clinical examination, chest X-
ray and echocardiography were utilized to make diagnosis of
valvular heart disease. There were 914 AFVHD patients and 2507
NVAF patients enrolled. Follow up was done at one-month, six
months and at one-year. One-month follow-up was exclusively
clinic visit and six month and one-year visits were either clinic visit
or telephonic contact. Among the total 2507 patients, we could
follow up 97.4% at one month, 88.9% at six month and 84.1% at one-
year (Fig. 1).57Details of co-morbidities and co-existing diseases were
assessed. Treatment details collected included drugs used for rate/
rhythm control as well as for stroke prevention. Stroke and
bleeding risk of patients were assessed using CHA2DS2-VASc and
HAS-BLED score.15,16 If death occurred, cause of death was noted.
Additionally, data on clinical events such as stroke, transient
ischemic attack (TIA), arrhythmia, systemic embolism other than
stroke, gastro-intestinal (GI) bleed, intra cranial (IC) bleed and
minor bleed were collected. Details of causes of hospitalization
were also noted. Estimated glomerular filtration rate
(eGFR) < 60 mL/min/1.73 m2 was taken as chronic kidney disease
(CKD).17
The study was conducted according to the ethical guidelines of
Indian Council of Medical Research (ICMR) and conforms to the
ethical guidelines of the 1975 Declaration of Helsinki. Informed
written consent was taken from each participant and the study was
approved by the ethics committees of the collaborating institutions.
This study was supported by the Cardiological Society of India,
Kerala Chapter (CSIeK).
Continuous variables were reported as mean ± SD and/or me-
dian and interquartile range (IQR). Categorical variables were re-
ported as percentages. Univariate analyses were applied to both
continuous and categorical variables. A p-value of <0.05 was
considered as statistically significant. Data was entered using Epi
Data Entry 3.1 version software18 and analysed using R software19
and Microsoft Excel package.
3. Results
3.1. Baseline characteristics
The mean age of study patients was 67.2 years (SD ± 13) (range:
18e98) and 54.8% were males. The mean CHA2DS2-VASc score was
3.2 (SD ± 1.7) and HAS-BLED score was 1.8 (SD ± 1.2). Most prev-
alent co-morbidities were hypertension (61.2%), followed by
hyperlipidaemia (46.2%) and diabetes mellitus (DM) (37.2%). Major
co-existing diseases were CKD (42.1%), coronary artery disease
(CAD) (41.6%), and chronic heart failure (CHF) (26.4%). Paroxysmal,
persistent and permanent AF were present in 45.6%, 14.9% and
39.4% of patients respectively. Baseline characteristics including
NYHA classes were presented in Table 1. DM, Hyperlipidaemia and
CAD were significantly higher in males and thyroid disease was
more in females.
3.2. Treatment pattern
3.2.1. Rate and rhythm control drugs
Strategy of rate control was used in 72.8% and rhythm control in
27.2% of patients. Betablocker was the most commonly used rate/
rhythm control drug (47.9%), followed by Digoxin (24.8%) and
Fig. 1. Kerala AF Registry NVAF patient’s follow-up
Table 1
Baseline characteristics of NVAF patients by sex.
Baseline Characteristics Male (N¼ 1375) n (%) Female (N¼ 1132) n (%) Total (N¼ 2507) n (%) P value
Age (in years) Median (IQR) 68(60e76) 69 (60e76) 68(60e76) 0.57
Mean (SD) 67.0(13.0) 67.3 (13.0) 67.2 (13.0) 0.59
CHA2DS2-VASc score (Mean± SD) 2.82± 1.68 3.61± 1.71 3.18± 1.74 <0.05
HAS-BLED score (mean± SD) 1.88± 1.29 1.79± 1.27 1.84± 1.29 0.059
Risk factors
Hypertension 839(61.0) 695(61.4) 1534(61.2) 0.869
Diabetes mellitus 540(39.3) 392(34.6) 932(37.2) <0.001
Dyslipidemia 665(48.4) 494(43.6) 1159(46.2) <0.001
Co-existing diseases
Stroke/TIA or Systemic Embolism 188(13.7) 165(14.6) 353(14.1) 0.526
Coronary Artery Disease 693(50.4) 351(31.0) 1044(41.6) <0.001
Chronic Heart Failure 376(27.3) 286(25.3) 662(26.4) 0.237
Chronic Liver Disease 33(2.4) 20(1.8) 53(2.1) 0.329
Respiratory Disease 312 (22.7) 223(19.7) 535(21.3) 0.038
Thyroid Disease 193(14.0) 251(22.2) 444(17.7) <0.001
Chronic Kidney Disease 541 (51.3) 513 (48.7) 1054 (42.1) 0.073
NYHA
Class I & II 1139(82.8) 934(82.5) 2073(82.6) 0.710
Class III & IV 232(16.9) 198(17.5) 430(17.2)
AF Classification
Paroxysmal AF 645(47.6) 500(44.2) 1145(45.6) 0.116
Persistent AF 213(15.5) 161(14.2) 374(14.9)
Permanent AF 516(37.5) 471(41.6) 987(39.4)
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the time of entry into the study,14 patients had a history of catheter
ablation,115 had pacemaker implantation, three had surgery for AF,
eleven had implantable cardioverter defibrillator (ICD) and six had
left atrial (LA) appendage occlusion.
3.2.2. Oral anticoagulants (OACs)
Themost commonly used OACwas Vitamin K Antagonists (VKA)
58.2% . Patients receiving OAC showed an increase from 38.6% at the
time of recruitment to 65.8% at one-month follow-up, and the use
of NOAC increased from 2.7% to 7.6%. Among 2064 (82.3%) patients
who had CHA2DS2-VASc score  2, the use of OAC was 39.2% which
was increased to 67.8% at one-month follow-up. Patients with
CHA2DS2-VASc score of 1 also received OAC at baseline (37.9%),
which was increased to 55.7% at one-month follow-up (Figs. 2 and
3). Although 58.2% of patients were receiving VKA, International58Normalised Ratio (INR) monitoring and dose adjustments were
inadequate. Among those who were on VKA treatment 51.0% were
aware of their INR values at one-month and 58.6% at six month and
77.3% at one-year.3.2.3. Antiplatelets
At baseline, 32.7% of patients were receiving antiplatelets which
increased to 48.3% on one-month follow-up (Fig. 2). Among pa-
tients with CHA2DS2-VASc score 2, 33.2% of patients were treated
with antiplatelets which increased to 49.1% at one-month follow-
up. In 23.0% of patients with CHA2DS2-VASc score of 1 and 39.4%
of CHA2DS2-VASc score 4 were on antiplatelets at baseline. Both
groups showed an increase in the use of antiplatelets on one-
month follow up, 36.1% and 57.1% respectively (Figs. 3 and 4).
Fig. 2. Use of antithrombotics at baseline and at 1 month follow-up
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During one-year follow-up, all-cause mortality of 16.48/100
person years was observed. Cardiac death was 12.36/100 person
years. Majority of death were cardiac (75.0%), followed by stroke
(13.1%) and others (11.9%). Nearly half of the deaths (49%) were for
patients with paroxysmal AF followed by permanent AF (35%) and
persistent AF (16%).
Among the total 431 patients (20.65/100 person years) who
required hospitalization, majority were due to acute coronary
syndrome (ACS), followed by arrhythmia and heart failure (Table 2).4. Discussion
KERALA-AF Registry is the largest and comprehensive study on
AF from India. NVAF constituted the major portion of patients in
this cohort unlike the earlier studies from India which reported
high prevalence of rheumatic valvular heart disease.20,21 The mean
age of patients (67.2 years) in this studywas similar to themean age
of Indian cohort (65.8 years) of GARFIELD-AF registry.22 Prevalence
of risk factors and co-existing diseases were relatively higher. CADFig. 3. Use of antithrombotics at baseline
59and risk factors like DM, hyperlipidaemia were higher than the
average reported in the Indian as well as non-Indian patients of
GLORIA-AF23 and GARFIELD-AF24 registries (TATable 3). Prevalence
of hypertension, in this cohort was similar to what was reported in
many other AF registries.9,22,23 CKD was found to be high (42.1%) in
our study. A relatively higher prevalence of these life style diseases
and cardiovascular risk factors observed in this registry might be a
reflection of higher prevalence in general population of Kerala. The
influence of coronary risk factors, like DM, hyperlipidaemia and
hypertension on the observed higher incidence of ACS in this study
requires further evaluation.
The mean CHA2DS2-VASc score of patients in this registry was
similar to what was reported in the European cohort of GLORIA-AF,
GARFIELD-AF and EORP-AF registries and higher than the Indian
cohort of GARFIELD-AF registry. The use of OAC at baseline (38.6%)
was much lower than what was reported in EORP-AF registry
(78.7%). Among patients with CHA2DS2-VASc score 2, those who
were not receiving OAC at baseline was 60.8% as compared to 31.9%
in the GARFIELD-AF registry. HAS-BLED score in general has not
been considered for selection of anti-thrombotic drugs in this
cohort. It was observed that OAC usage in patients with HAS_BLED
score 3, and 2 were not significantly different, 68.1% and 63.5%
respectively. Neither the bleeding risk nor the associated co-
morbidities do not seem to have influenced the use of OACs. Low
OAC use reflected its inadequate usage for stroke prevention in
NVAF patients in Kerala. Even though the commonly used OAC was
VKAs in this registry, its use was suboptimal because of unsatis-
factory INRmonitoring, dose adjustments and lack of compliance to
therapy.
The overall use of NOAC among KERALA-AF Registry patients
(7.6%) was low, similar to what was reported in Indian Heart
Rhythm Society-Atrial Fibrillation (IHRS-AF) registry (4%).25 In
GLORIA-AF Registry, the use of NOAC varied among patients
recruited from different countries ranging from 20% in Asia to 52%
in North America. Although NOAC is the preferred drug for stroke
prevention in AF as per guideline recommendations,26,27 the cost
considerations and wide difference in prescription practices among
physicians might contribute to lower use of NOACs in Kerala.
Use of antiplatelets was 48.3% (single antiplatelet therapy
(35.1%) and dual antiplatelet (13.2%) which was high whenin relation to CHA2DS2-VASC score
Fig. 4. Use of antithrombotics at 1 month follow-up in relation to CHA2DS2-VASC score
Table 2
Death and non-fatal Hospitalization at each time point within one-year.
Clinical Events 1 Month (N ¼ 2441) 1e6 Months (N ¼ 2173) 6e12 months (N ¼ 1892) Cumulative 1 Year (/100 person years)
All cause Death 55 162 127 344 (16.48)
Cardiac 45 118 95 258 (12.36)
Stroke 6 18 21 45 (2.16)
Others 4 26 11 41 (1.96)
Non-fatal Hospitalization (n (%)) 101 161 169 431 (20.65)
Stroke 11 11 17 39 (1.87)
Transient Ischemic Attack 0 6 6 12 (0.57)
Arrhythmia 21 39 67 127 (6.08)
Acute Coronary Syndrome 28 71 52 151 (7.23)
Heart Failure 27 18 17 62 (3.02)
Systemic Embolism other than stroke 0 4 2 6 (0.28)
Gastro intestinal bleed 7 5 4 16 (0.77)
Intracranial Bleed 1 1 0 2 (0.09)
Minor Bleed 6 6 3 15 (0.72)
C.G. Bahuleyan, N. Namboodiri, A. Jabir et al. Indian Heart Journal 73 (2021) 56e62compared to other studies conducted worldwide.9,22,23 GLORIA-AF
Registry reported antiplatelet usage as 6.0% in European, 14% in
North American and 25% in Asian cohorts. Other Indian studies
have also shown high usage of antiplatelets among the population
with highest risk of stroke. In the Indian cohort of the Realise-AF
Registry,20 58% received only antiplatelet therapy for prevention
of stroke. In IHRS-AF Registry, 30% of patients received only anti-
platelet as stroke prevention treatment. The higher prevalence of
CAD in this cohort might have contributed to the increased use of
antiplatelets.
5. Outcome
One-year mortality per 100 person years was 16.48 in KERALA-
AF Registry, which was 7.8 for Indian cohort of GARFIELD-AF Reg-
istry and 4.3 in Global GARFIELD-AF Registry. IHRS- AF registry
reported an annual all cause death of (6.5%). RELY-AF Registry28
reported 11% death in one-year in patients presenting to emer-
gency department with AF in 47 countries with marked difference
between participant countries with 20% in Africa, 17% in South
America and 10% in North America, Europe and Australia.29 In
KERALA-AF Registry, majority (75%) of death were due to cardiac
causes, similar to what was observed in the Indian cohort of
GARFIELD-AF Registry. The rate of hospitalization was 20.65/10060person years and majority were due to cardiac causes. This is
relatively higher than previously reported rate of hospitalizations
in other registries from India, including IHRS-AF Registry. The
increased rate of cardiac death and hospitalization due to ACS is
probably indicative of a greater extent of CAD. A detailed evaluation
of multimorbidity among these patients is required to clarify this
issue.
5.1. Limitations
The registry data will not reflect the true incidence or preva-
lence of NVAF in the population since this is a hospital-based study.
For VKA treated patients, other than the three time point INR
values, we do not have enough data to comment on INRmonitoring
and dose adjustments.
6. Conclusion
High propensity of risk factors like hypertension, hyper-
lipidaemia, diabetes mellitus, and co-existing diseases like CAD,
CKD has been observed among NVAF patients in Kerala AF Registry.
Despite high stroke risk, a good proportion of patients were not
receiving OAC whereas nearly half were treated with antiplatelets.
Though most commonly used anticoagulant was VKAs, INR
Table 3
Risk factors and co-morbidities of published NVAF registries.
KERALA-AF Registry (NVAF)
(N ¼ 2507)

















71.0(IQR 64e79) 70.5 (IQR 64
e78)
Age  75 30.0 26.3 37.2 28.5 44.3 39.6 39.1
Female (%) 45.2 40.1 43.8 43.5 46.7 44.8 45.5
Hypertension (%) 61.2 68.5 76.3 69.4 73.4 80.5 74.6
Diabetes mellitus (%) 37.2 36.2 22.2 20.2 21.2 27.1 23.1
Hyperlipidemia (%) 46.2 13.6 41.6 26.7 36.5 61.3 39.9
Stroke/TIA (%) 14.1 9.1 11.4 13.0 15.6 12.4 14.2
Coronary Artery Disease (%) 41.6 28.1 21.6 21.9 16.4 27.0 20.3
Chronic Heart Failure (%) 26.4 15.5 20.6 27.3 23.4 19.7 24.2
Chronic Kidney Disease (%) 42.1 5.2 10.3 e e e 17.3
CHA2DS2-VASc score (mean/
median)
3.2(±1.74) 2.9 (±1.5) 3.2 (±1.6) 3(2e4) 3 (2e4) 3 (2e4) 3.2
HASBLED (mean or Median) 1.8(±1.3) 1.5(±0.9) 1.4(±0.9) 1.0(IQR 1e2) 1.0(IQR 1e2) 1.0(IQR 1e2) 1.0(IQR 1e2)
Paroxysmal AF (%) 45.6 16.4 25.2 58.1 46.8 65.8 53.4
Persistent AF (%) 14.9 8.5 15.6 35.4 38.9 29.6 35.5
Permanent AF (%) 39.4 10.4 13.2 5.9 14.3 4.6 11.1
OAC (%) 65.8 35.5 80.0 55.2 90.1 78.3 79.9
NOAC (%) 7.6 6 47.7 25.5 52.4 52.1 47.6
VKA (%) 58.2 29.5 32.3 31.9 37.8 26.2 32.3
Antiplatelet (%) 48.3 43.3 12.3 25.8 6.0 14.0 12.1
No Antithrombotic agents (%) 16.0 21.4 7.6 16.9 3.8 7.5 7.8
All cause death/100 person
years
16.48 7.8 4.34 e e e e
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higher rate of annual mortality and hospitalization was observed.
The study brings out high-risk characteristics of patients, higher
annual mortality and hospitalization, inadequacies of treatment
and need for improvement in the care of NVAF patients.Funding
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